This website uses cookies
Read our Privacy policy and Terms of use for more information.
All Posts
/
Oct 9, 2026
In this issue: A deeper look at biopharma’s exposure to interest rates and inflation, plus the launch of San Diego Spotlight with a feature on Catalent’s San Diego facilities.
Oct 2, 2026
Plus: Anthropic’s AI biology flashpoint, Breztri’s European asthma approval, and Breye’s €67.5M bet on oral eye-disease therapies.
Sep 25, 2026
Plus: FDA CRLs reveal manufacturing pressure and a biologics pivot, Egypt’s WHO rating re-energizes pharma, and Novo Nordisk brings Anthropic into AI-assisted R&D.
Sep 11, 2026
Plus: Superluminal raises $60M, recent FDA complete response letters expose interdependent filing risks, Novartis and Ionis face a Phase 3 Lp(a) setback, and BioKnow asks why chronic kidney disease is still being found too late.
Aug 31, 2026
Plus: GSK expands Tivicay for HIV-affected newborns, Huawei pushes deeper into AI pharma, Cellares restructures after losing a client, and BioKnow asks whether Parkinson’s trials are missing the real treatment window.
Aug 24, 2026
Plus: remote stroke robotics, a new EU myeloma approval, Werewolf’s reverse merger, and the human-centred models challenging animal testing.
Aug 17, 2026
Plus: Royalty Pharma’s $100M rusfertide royalty deal, NWBio’s Saudi expansion plans, and Vertex’s latest market momentum.
Regulatory
+2
Aug 10, 2026
Plus: Korean pharma's push into Latin America, and whether whole brain emulation is real science
Funding
Aug 5, 2026
Plus: Ratio raises $70M to scale radiopharma manufacturing, and Obsidian closes the Galera merger with $350M behind it
